The present invention relates to novel amino acid esters of arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
Claims What is claimed is: 1. A compound of the general formula (I) in which R.sup.1 represents a radical of the formula ##STR66## in which a represents a number 1 or 2, and where all of the phenyl ring systems listed above are optionally substituted, optionally geminally, by one or more identical or different substituents selected from the group consisting of: halogen, carboxyl, hydroxyl, phenyl, (C.sub.1 -C.sub.6)-alkoxy, (C.sub.1 -C.sub.6)-alkoxycarbonyl, (C.sub.1 -C.sub.8)-alkyl, which for its part may be substituted by halogen, (C.sub.1 -C.sub.6)-alkylsulphonyloxy, azide, amino, mono(C.sub.1 -C.sub.6)-alkylamino, di(C.sub.1 -C.sub.6)-alkylamino or hydroxyl, a group of the formula --(CO).sub.b --NR.sup.4 R.sup.5, in which b represents a number 0 or 1, R.sup.4 and R.sup.5 are identical or different and independently of one another represent hydrogen, phenyl, (C.sub.1 -C.sub.6)-acyl, cyclo(C.sub.4 -C.sub.7)-acyl benzoyl or (C.sub.1 -C.sub.6)-alkyl, which is optionally substituted by amino, mono(C.sub.1 -C.sub.6)-alkylamino, di(C.sub.1 -C.sub.6)-alkylamino, or R.sup.4 and R.sup.5 together with the nitrogen atom form a 5- or 6-membered saturated heterocycle which may optionally contain one or more further heteroatom(s) from the group consisting of S and O and/or one or more radical(s) of the formula --NR.sup.8, in which R.sub.8 represents hydrogen, (C.sub.1 -C.sub.6)-alkyl or (C.sub.1 -C.sub.6)-acyl, and a group of the formula --NR.sup.6 --SO.sub.2 --R.sup.7 in which R.sup.6 represents hydrogen, phenyl, (C.sub.1 -C.sub.6)-alkyl or (C.sub.1 -C.sub.6)-acyl, R.sup.7 represents phenyl or (C.sub.1 -C.sub.6)-alkyl, Q represents a radical of the formula ##STR67## in which c represents a number 1, 2, 3, 4, 5 or 6, R.sup.9 and R.sub.10 are identical or different and represent hydrogen or (C.sub.1 -C.sub.6)-alkyl, T represents a radical of the formula --(CH.sub.2).sub.d --, in which d represents a number 1, 2, 3, 4, 5, 6, 7 or 8, or T represents a moiety of an amino acid radical of the formula ##STR68## in which R.sup.13 and R.sup.14 are identical or different and represent hydrogen or methyl, or R.sup.13 represents hydrogen or methyl and R.sup.14 represents (C.sub.3 -C.sub.8)-cycloalkyl or (C.sub.6 -C.sub.10)-aryl or hydrogen, or (C.sub.1 -C.sub.8)-alkyl, where the (C.sub.1 -C.sub.6)-alkyl is optionally substituted by methlythio, hydroxyl, mercapto, guanidyl or by a group of the formula --NR.sup.15 R.sup.16 or --NR.sup.17 --OC--, in which R.sup.15 and R.sup.16 independently of one another represent hydrogen, (C.sub.1 -C.sub.8)-alkyl or phenyl and R.sup.17 represents hydroxyl, benzyloxy, (C.sub.1 -C.sub.8)-alkoxy or the group --NR.sup.15 R.sup.16 listed above, or the (C.sub.1 -C.sub.8)-alkyl is optionally substituted by (C.sub.3 -C.sub.6)cycloalkyl or phenyl, which for its part is substituted by hydroxyl, halogen or (C.sub.1 -C.sub.6)-alkoxy or amino, or the (C.sub.1 -C.sub.8)-alkyl is optionally substituted by imidazolyl or indolyl, in which the corresponding --NH functions are optionally protected by (C.sub.1 -C.sub.6)-alkyl or by an amino protective group, R.sup.11 and R.sup.12 are identical or different and represent hydrogen, (C.sub.1 -C.sub.6)-alkyl or a typical amino protective group, or R.sup.11 and R.sup.12 together with the nitrogen atom form a 5- to 6-membered saturated heterocycle, which may optionally contain a further heteroatom from the group consisting of S and O or a radical of the formula --NR.sup.18, in which R.sup.18 represents hydrogen, (C.sub.1 -C.sub.6)-alkyl or phenyl, A and E are identical or different and represent a bond or represent (C.sub.1 -C.sub.4)-alkylene, D represents an oxygen atom or represents a radical of the formula --S(O).sub.e -- or --N(R.sup.19)--, in which e represents a number 0, 1 or 2, R.sup.19 represents hydrogen, (C.sub.1 -C.sub.6)-alkyl or (C.sub.1 -C.sub.6)-acyl, G represents doubly attached (C.sub.6 -C.sub.10)-aryl or represents a doubly attached 5- to 7-membered aromatic heterocycle having up to 3 heteroatoms from the group consisting of S, N and O, which are optionally substituted by one or more identical or different substituents selected from the group consisting of: hydroxyl, trifluoromethyl, carboxyl, halogen, (C.sub.1 -C.sub.6)-alkyl, hydroxy(C.sub.1 -C.sub.6)-alkyl, (C.sub.1 -C.sub.6)-alkoxy, (C.sub.1 -C.sub.6)-alkoxycarbonyl, and groups of the formulae --CO--O--(CH.sub.2).sub.f --NR.sup.20 R.sup.21, --NR.sup.22 --SO.sub.2 R.sup.23, --(CH.sub.2).sub.g --(CO).sub.h --NR.sup.24 R.sup.25 and --OR.sup.26, in which f represents a number 1, 2, 3 or 4, g and h are identical or different and represent a number 0 or 1, R.sup.20 and R.sup.21 have the meaning of R.sup.4 and R.sup.5 given above and are identical to or different from this meaning, R.sup.22 has the meaning of R.sup.6 given above and is identical to or different from this meaning, R.sup.23 has the meaning of R.sup.7 given above and is identical to or different from this meaning, R.sup.24 and R.sup.25 have the meaning of R.sup.4 and R.sup.5 given above and are identical to or different from this meaning, or independently of one another represent a radical of the formula and pharmaceutically acceptable salts thereof. 2. A compound of the general formula (I) according to claim 1, in which R.sup.11 and R.sup.12 are identical or different and represent hydrogen or (C.sub.1 -C.sub.6)-alkyl, or R.sup.11 and R.sup.12 together with the nitrogen atom form a 5- to 6-membered saturated heterocycle which may optionally contain a further heteroatom from the group consisting of S and O or a radical of the formula --NR.sup.18, in which R.sup.18 represents hydrogen, (C.sub.1 -C.sub.6)-alkyl or phenyl, and pharmaceutically acceptable salts thereof. 3. A compound of the general formula (I) according to claim 1, in which R.sup.1 represents a radical of the formula ##STR73## in which represents a number 1 or 2, and where the phenyl radical listed above is optionally substituted, optionally geminally, by one or more identical or different substituents selected from the group consisting of: fluorine, chlorine, carboxyl, hydroxyl, (C.sub.1 -C.sub.4)-alkoxy, (C.sub.1 -C.sub.5)-alkoxycarbonyl or (C.sub.1 -C.sub.6)-allyl, which for its part may be substituted by fluorine, chlorine or hydroxyl, Q represents a radical of the formula ##STR74## in which c represents a number 1, 2, 3, 4, 5 or 6, R.sup.9 and R.sup.10 are identical or different and represent hydrogen or (C.sub.1 -C.sub.6)-alkyl, T represents a radical of the formula --(CH.sub.2).sub.d --, in which d represents a number 1, 2, 3, 4, 5 or 6, or T represents a moiety of an amino acid radical of the formula ##STR75## in which R.sup.13 represents hydrogen or methyl and R.sup.14 represents cyclopropyl, cyclopentyl, cyclohexyl, phenyl or hydrogen, or represents (C.sub.1 -C.sub.6)-alkyl, where the (C.sub.1 -C.sub.6)-alkyl is optionally substituted by methlythio, hydroxyl, mercapto, guanidyl or by a group of the formula --NR.sup.15 R.sup.16 or --NR.sup.17 --OC--, in which R.sup.15 and R.sup.16 independently of one another represent hydrogen, (C.sub.1 -C.sub.6)-alkyl or phenyl and R.sup.17 represents hydroxyl, benzyloxy, (C.sub.1 -C.sub.6)-alkoxy or the group --NR.sup.15 R.sup.16 listed above, or the (C.sub.1 -C.sub.6)-alkyl is optionally substituted by cyclopropyl, cyclopentyl, cyclohexyl or phenyl, which for its part is substituted by hydroxyl, fluorine, chlorine, bromine or (C.sub.1 -C.sub.4)-alkoxy or amino, and R.sub.11 and R.sup.12 are identical or different and represent hydrogen or (C.sub.1 -C.sub.4)-alkyl, or R.sup.11 and R.sup.12 together with the nitrogen atom form a morpholinyl, piperidinyl or piperazinyl ring, A and E are identical or different and represent a bond or represent (C.sub.1 -C.sub.4)-alkylene, D represents an oxygen atom, G represents doubly attached phenyl, naphthyl, pyrimidyl, pyradizinyl or pyridyl, which are optionally substituted by one or more identical or different substituents selected from the group consisting of: hydroxyl, trifluoromethyl, carboxyl, halogen, (C.sub.1 -C.sub.4)-alkyl, hydroxy(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)-alkoxy and (C.sub.1 -C.sub.4)-alkoxycarbonyl L represents a radical of the formula ##STR76## where the left-hand side of the radicals is attached to G, R.sup.2 represents (C.sub.1 -C.sub.10)-alkyl which is optionally substituted by one or more identical or different substituents selected from the group consisting of: fluorine, chlorine, bromine, phenyl, trifluoromethyl, hydroxyl, azido, (C.sub.1 -C.sub.4)-alkoxy, (C.sub.1 -C.sub.5)-perfluoroalkoxy or partially fluorinated (C.sub.1 -C.sub.4)alkoxy and pharmaceutically acceptable salts thereof. 4. A compound of the general formula (I), according to claim 1 in which R.sup.1 represents a radical of the formula ##STR77## in which a represents a number 1 or 2, and where the phenyl radical listed above is optionally substituted by one or more identical or different substituents selected from the group consisting of: chlorine, fluorine, hydroxyl, (C.sub.1 -C.sub.3)-alkoxy or (C.sub.1 -C.sub.4)-alkyl, which for its part may be substituted by hydroxyl, Q represents a radical of the formula ##STR78## in which c represents a number 1, 2, 3 or 4, R.sup.9 and R.sup.10 are identical or different and represent hydrogen or (C.sub.1 -C.sub.3)-alkyl, T represents a radical of the formula --(CH.sub.2).sub.d --, in which d represents a number 1, 2, 3, 4, 5 or 6, or T represents a moiety of an amino acid radical of the formula ##STR79## in which R.sup.13 represents hydrogen or methyl and R.sup.14 represents cyclopentyl, cyclohexyl, phenyl or hydrogen, or represents (C.sub.1 -C.sub.4)-alkyl, where the (C.sub.1 -C.sub.4)-alkyl is optionally substituted by methlythio, hydroxyl, mercapto, guanidyl or by a group of the formula --NR.sup.15 R.sup.16 or --NR.sup.17 --OC--, in which R.sup.15 and R.sup.16 independently of one another represent hydrogen, (C.sub.1 -C.sub.8)-alkyl or phenyl and R.sup.17 represents hydroxyl, benzyloxy, (C.sub.1 -C.sub.3)-alkoxy or amino, or the (C.sub.1 -C.sub.4)-alkyl is optionally substituted by cyclopentyl, cyclohexyl or phenyl, which for its part is substituted by hydroxyl, fluorine, chlorine or (C.sub.1 -C.sub.3)-alkoxy or amino, and R.sup.11 and R.sup.12 are identical or different and represent hydrogen or (C.sub.1 -C.sub.3)-alkyl, or R.sup.11 and R.sup.12 together with the nitrogen atom form a morpholinyl ring, A and E represent a bond, D represents an oxygen atom, G represents doubly attached phenyl which are optionally substituted by one or more identical or different substituents selected from the group consisting of: hydroxyl, trifluoromethyl, carboxyl, fluorine, chlorine, bromine, (C.sub.1 -C.sub.3)-alkyl, hydroxy(C.sub.1 -C.sub.3)alkyl or (C.sub.1 -C.sub.3)-alkoxy L represents a radical of the formula ##STR80## were the left-hand side of the radicals is attached to G, R.sup.2 represents (C.sub.1 -C.sub.8)-alkyl, which is optionally substituted by one or more identical or different substituents selected from the group consisting of: fluorine, chlorine, bromine, phenyl, trifluoromethyl or trifluoromethyl-substituted (C.sub.1 -C.sub.4)-alkoxy, and pharmaceutically acceptable salts thereof. 5. A compound of the general formula (I), according to claim 1, in which R.sup.1 represents a radical of the formula ##STR81## in which Q represents a radical of the formula ##STR82## in which T represents a radical of the formula --(CH.sub.2).sub.d --, in which d represents a number 1, 2, 3, 4, 5 or 6, or T represents a moiety of an amino acid radical of the formula ##STR83## in which R.sup.13 represents hydrogen, and R.sup.14 represents hydrogen, (C.sub.1 -C.sub.4)-alkyl, benzyl or a radical of the formula --CH.sub.2 OH, A and E represent a bond, D represents an oxygen atom, G represents phenyl, which is optionally substituted by fluorine, chlorine or brominie, L represents a radical of the formula ##STR84## where the left-hand side of the radical is attached to G, R.sup.2 represents (C.sub.1 -C.sub.4)-alkyl, which is optionally substituted by fluorine or trifluoromethyl, and pharmaceutically acceptable salts thereof. 6. A compound selected from the group consisting of (R)-3-(2-glycinyl-oxymethyl-indanyl-4-oxy)-phenyl 4,4,4-trifluoro-1-butanesulphonate ##STR85## (R)-3-[2-(7-aminoheptanoyloxymethyl)-indanyl-4-oxy]-phenyl 4,4,4-trifluoro-1-butanesulphonate ##STR86## (R)-3-[2-(3-aminopropanoyloxymethyl)-indanyl-4-oxy)-phenyl 4,4,4-trifluoro-1-butanesulphonate ##STR87## (R)-3-[2-((S)-valinyloxymethyl)-indanyl-oxy]-phenyl 4,4,4-trifluoro-1-butanesulphonate ##STR88## and phamaceutically acceptable salts thereof. 7. A process for preparing the compounds of the general formula (I) according to the invention, comprising: reacting compounds of the general formula (II) and removing the amino protective group. 8. Process for preparing compounds of the general formula (IIk) ##STR91## in which A, D, E, G, L and R.sup.2 have the meaning given above, characterized in that the compounds of the general formula (III) ##STR92## in which A, D, E, G, L and R2 have the meaning given above are converted, by using HBr and acetic acid, into the compounds of the general formula (IIm) ##STR93## in which A, D, E, G, L and R2 have the meaning given above, and, in a last step, a reduction with BH.sub.3.times.S(CH.sub.3).sub.2 in tetrahydrofuran is carried out, and, in the case of the pure enantiomers, an HPLC separation by customary methods is carried out. 9. A pharmaceutical composition which comprises, as active component, at least one compound according to claim 1 in combination with at least one pharmaceutically acceptable essentially non-toxic vehicle or excipient. 10. A method of treating or preventing a neurodegenerative disorder, comprising administering to a mammal an effective amount of a compound according to claim 1. 11. A method of treating or preventing cerebral ischaemias and craniocerebral trauma, comprising administering to a mammal an effective amount of a compound according to claim 1. 12. A method of treating states of pain, emesis, nausea, glaucoma, asthma, anorexia, convulsions, rheumatism, sedation and mobility disorders, comprising administering to a mammal an effective amount of a compound according to claim 1. 13. A method of treating bacterial or viral infections, autoimmune diseases, inflammatory or autoimmunologically related diseases of the joints, bone, muscle, internal and external organs, central nervous system, sense organs and haematogenic system, comprising administering to a mammal an effective amount of a compound according to claim 1. 14. A method of treating migraine and spasticity, comprising administering to a mammal an effective amount of a compound according to claim 1. 15. The process of claim 7, wherein, after removal of the amino protective group, the amino group is reductively alkylated or dialkylated with an aldehyde, ketone or halide. 16. The process of claim 15, wherein said compound of formula I is esterified. 17. The process of claim 7 wherein said amino protective group R.sub.12' of said compound of formula (III) is a tert-butyloxycarbonyl group. 